Key facts
- This page summarizes Herb Cross's Form 4 filing for Apexigen, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 25 Aug 2023, 19:24.
Herb Cross - 23 Aug 2023 Form 4 Insider Report for Apexigen, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 23 Aug 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Aug 2023, 19:24:18 UTC
- Prior SEC filing
- 04 Aug 2023
- Next SEC filing
- 26 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Francis Sarena, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Herb Cross filed Form 4 for Apexigen, Inc. on 25 Aug 2023.
Change
- Previous filing in this sequence was filed on 04 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APGN
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -34,084
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 23 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 34,084
- Exercise price
- $6.94
- Footnotes
- F1
APGN
transaction
Derivative
Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -100,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 23 Aug 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $2.65
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Herb Cross is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The shares subject to the option vest in 48 equal monthly installments beginning on November 3, 2019. Pursuant to an Agreement and Plan of Merger, dated as of May 23, 2023 (the "Merger Agreement"), by and among the Issuer, Pyxis Oncology, Inc. ("Pyxis"), and Ascent Merger Sub Corp., at the effective time of the merger (the "Effective Time"), the option was assumed by Pyxis and converted into an option to purchase 5,879 shares of Pyxis common stock at an exercise price of $40.24 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.
Footnote F2
The shares subject to the option vest in three equal annual installments beginning on July 29, 2023. Pursuant to the Merger Agreement, at the Effective Time, the option was assumed by Pyxis and converted into an option to purchase 17,250 shares of Pyxis common stock at an exercise price of $15.37 per share. In accordance with the reporting person's equity award agreement, vesting of the unvested shares underlying the option accelerated in full at the Effective Time.